Product Center
Abundant Achievements Showcasing Technological Strength
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-12-15
- Views:
(Summary description)Recently, a press conference on the evaluation results of unicorn and gazelle enterprises in Jiangsu High-Tech Zone was held in Nanjing. Ab&B Bio-Tech Co., Ltd. JS was recognized as a Potential Unicorn Enterprise in Jiangsu Province.
Abundant Achievements Showcasing Technological Strength
(Summary description)Recently, a press conference on the evaluation results of unicorn and gazelle enterprises in Jiangsu High-Tech Zone was held in Nanjing. Ab&B Bio-Tech Co., Ltd. JS was recognized as a Potential Unicorn Enterprise in Jiangsu Province.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-12-15 16:19
- Views:
Recently, a press conference on the evaluation results of unicorn and gazelle enterprises in Jiangsu High-Tech Zone was held in Nanjing. Ab&B Bio-Tech Co., Ltd. JS was recognized as a Potential Unicorn Enterprise in Jiangsu Province.
Potential Unicorn Enterprises in Jiangsu Province are innovative companies with strong innovation capabilities, rapid growth, and significant development potential. They serve as indicators of urban innovation vitality and industrial ecosystems, characterized by high growth potential, strong innovation capacity, and vast market opportunities. These enterprises are key drivers of industrial transformation in the new economy sector. This recognition as a Potential Unicorn Enterprise is a testament to the company’s innovation and development capabilities, as well as strong evidence of Zhonghui Biotechnology’s technological prowess. Recently, the company has achieved significant milestones in technological innovation. Its independently developed freeze-dried human rabies vaccine (human diploid cell-based) has made notable progress, obtaining implied clinical trial approval from the National Medical Products Administration (NMPA). This product marks the fifth candidate from the company to enter clinical trials, further expanding its product pipeline and demonstrating its technological leadership.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
